Table 1.
Baseline Characteristics of Patients (n = 532) With Prior Virologic Failure or Exposure to Mono/Dual NRTI Therapy According to ART Exposure Group
| Patient Characteristics Measured at Baseline (Index Date) | PWH Whose Regimen Was Switched to Dolutegravir With 2 NRTIs (n = 216) | PWH Whose Regimen Remained on PI/r With 2 NRTIs (n = 316) | |
|---|---|---|---|
| Age in years | Mean (SD) | 50.8 (9.5) | 52.6 (8.6) |
| Median (IQR) | 51.2 (44.9–56.9) | 52.4 (47.5–57.8) | |
| Sex, N (%) | Male | 190 (87.9%) | 272 (86.1%) |
| Female | 26 (12.1%) | 44 (13.9%) | |
| Risk factor for HIV acquisition, N (%) | MSM | 153 (70.8%) | 222 (70.2%) |
| Bisexual | 7 (3.2%) | 10 (3.2%) | |
| Heterosexual | 46 (21.3%) | 59 (18.7%) | |
| From endemic | 20 (9.3%) | 33 (10.4%) | |
| Vertical transmission | 2 (0.9%) | 1 (0.3%) | |
| Backbones, N (%) | Abacavir/lamivudine | 159 (73.6%) | 124 (39.2%) |
| Tenofovir disoproxil/ emtricitabine | 57 (26.4%) | 186 (58.9%) | |
| Tenofovir disoproxil/ lamivudine | 0 (0%) | 6 (1.9%) | |
| CD4 count (cells/mm3) | Mean (SD) | 675.9 (287.9) | 618.9 (288.9) |
| Median (IQR) | 621.5 (480.0–851.0) | 590.0 (430.0–748.0) | |
| HIV Infection duration (in year) | Mean (SD) | 15.3 (6.1) | 16.8 (4.9) |
| Median (IQR) | 15.9 (11.0–19.0) | 17.5 (15.5–19.3) | |
| ART duration (in years) | Mean (SD) | 13.6 (5.0) | 16.8 (4.9) |
| Median (IQR) | 15.2 (9.9–17.0) | 17.5 (15.5–19.3) | |
| Mutations 184V/I, N (%) | Yes | 25 (32.5%) | 59 (48.4%) |
| No | 52 (67.5%) | 63 (51.6%) | |
| Not tested | 139 | 194 | |
| Other NRTI mutationsa | Yes | 29 (37.7%) | 57 (46.7%) |
| No | 48 (62.3%) | 65 (53.3%) | |
| Not tested | 139 | 194 | |
| Previously documented virologic failure | Yes | 204 (94.4%) | 152 (48.1%) |
| No | 12 (5.6%) | 164 (51.9%) | |
| Previous exposure to mono/ dual NRTI therapyb | Yes | 64 (29.6%) | 217 (68.7%) |
| No | 152 (70.4%) | 99 (31.3%) | |
| Hepatitis B history, N (%) | Positive for HBsAg | 8 (3.7%) | 39 (12.3%) |
| Hepatitis C history, N (%) | Positive for anti-HCV | 28 (12.9%) | 46 (14.6%) |
Abbreviations: ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range (25%–75%); MSM, men who have sex with men; NRTI, nucleoside reverse-transcriptase inhibitor; PI/r, protease inhibitor/ritonavir; PWH, people with HIV; SD, standard deviation.
aOthers NRTIs mutations in mutation sites: M41, K65, D67, T69, K70, L74, Y115, Q151, L210, and T215.
bMonotherapy or dual therapy with 1 or 2 NRTIs for at least 1 month before baseline.